Podcast

The Risk of Risk

Much has been made of the American public's general lack of health literacy and the effect it has on patients' abilities to make informed health decisions.

Download the March 2009 cover story of MDNG/Oncology Net Guide to listen on your mp3 player.

MP3 DOWNLOAD:

MDNG-OncNG.mp3

(Right click to download podcast)

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
How to Manage Aspirin-Exacerbated Respiratory Disease
Related Content
Credit: Adobe Stock / Pormezz
December 16th 2024

High Prevalence of RLS Found in Patients with MDD, Migraine, Anxiety

Chelsie Derman
Video: Exploring Bempedoic Acid: Clinical Indications, Efficacy, and Future Directions in Cardiovascular Risk Management
December 17th 2024

Video: Exploring Bempedoic Acid: Clinical Indications, Efficacy, and Future Directions in Cardiovascular Risk Management

Pam R. Taub, MD, FACC, FASPC Marc P. Bonaca, MD, MPH
Aldosterone Dysregulation Linked to Notable Risk of Hypertension | Image Credit: CMHC
December 14th 2024

Aldosterone Dysregulation Linked to Notable Risk of Hypertension

Connor Iapoce
Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor
December 16th 2024

Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Mifepristone Significantly Reduces HbA1c in Treatment Phase of CATALYST | Image Credit: LinkedIn
December 12th 2024

Mifepristone Notably Reduces HbA1c in Treatment Phase of CATALYST Trial

Connor Iapoce
Credit: Christopher Gottschalk, MD I Yale Medicine
December 9th 2024

Atogepant Improves Quality of Life in Individuals with Chronic, Episodic Migraine

Chelsie Derman
© 2024 MJH Life Sciences

All rights reserved.